Avila gets new US patent
The new patent covers compositions of matter for a particular class of targeted covalent drugs that selectively and irreversibly inhibit kinases such as members of the epidermal growth
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.